BG105378A - Лечение на депресия - Google Patents

Лечение на депресия Download PDF

Info

Publication number: BG105378A
Authority: BG; Bulgaria
Prior art keywords: compound; treatment; day; depression; use according
Prior art date: 1998-09-15

Application number

BG105378A

Other languages

Bulgarian (bg)

English (en)

Inventor

Connie Sanchez

Original Assignee

H. Lundbeck A/S

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-09-15

Filing date

2001-03-23

Publication date

2001-12-29

2001-03-23 Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S

2001-12-29 Publication of BG105378A publication Critical patent/BG105378A/bg

Links

208000020401 Depressive disease Diseases 0.000 title claims abstract description 11
150000001875 compounds Chemical class 0.000 title claims description 24
239000003814 drug Substances 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 8
150000003839 salts Chemical class 0.000 claims description 13
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 4
239000012458 free base Substances 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
208000019022 Mood disease Diseases 0.000 claims description 2
208000024732 dysthymic disease Diseases 0.000 claims description 2
208000024714 major depressive disease Diseases 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 8
201000010099 disease Diseases 0.000 abstract description 3
230000001430 anti-depressive effect Effects 0.000 abstract description 2
229940125904 compound 1 Drugs 0.000 abstract description 2
206010054089 Depressive symptom Diseases 0.000 abstract 1
241001465754 Metazoa Species 0.000 description 21
230000000694 effects Effects 0.000 description 9
230000001684 chronic effect Effects 0.000 description 8
238000000034 method Methods 0.000 description 8
239000003982 sigma receptor ligand Substances 0.000 description 8
238000012360 testing method Methods 0.000 description 7
241000700159 Rattus Species 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
208000007415 Anhedonia Diseases 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000012442 inert solvent Substances 0.000 description 3
108010085082 sigma receptors Proteins 0.000 description 3
206010010904 Convulsion Diseases 0.000 description 2
208000011688 Generalised anxiety disease Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
208000025966 Neurological disease Diseases 0.000 description 2
208000028017 Psychotic disease Diseases 0.000 description 2
239000002249 anxiolytic agent Substances 0.000 description 2
230000000949 anxiolytic effect Effects 0.000 description 2
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
208000029364 generalized anxiety disease Diseases 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
238000011160 research Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
ZRYMMWAJAFUANM-INIZCTEOSA-N (7s)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5h-carbazole-1-carboxamide Chemical compound C1[C@@H](C(C)(C)O)CCC2=C1NC1=C2C(C2=C(C(=CC=C2)N2C(C3=CC=CC(F)=C3N(C)C2=O)=O)C)=C(F)C=C1C(N)=O ZRYMMWAJAFUANM-INIZCTEOSA-N 0.000 description 1
UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
229940126279 Compound 14f Drugs 0.000 description 1
102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000220225 Malus Species 0.000 description 1
235000011430 Malus pumila Nutrition 0.000 description 1
235000015103 Malus silvestris Nutrition 0.000 description 1
208000019430 Motor disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
101150069124 RAN1 gene Proteins 0.000 description 1
206010039966 Senile dementia Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010065604 Suicidal behaviour Diseases 0.000 description 1
ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
208000000323 Tourette Syndrome Diseases 0.000 description 1
208000016620 Tourette disease Diseases 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000020224 almond Nutrition 0.000 description 1
230000003496 anti-amnesic effect Effects 0.000 description 1
230000002253 anti-ischaemic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229940005530 anxiolytics Drugs 0.000 description 1
238000013142 basic testing Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
229960003920 cocaine Drugs 0.000 description 1
239000002475 cognitive enhancer Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000028436 dopamine uptake Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000009837 dry grinding Methods 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000005286 illumination Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000001932 seasonal effect Effects 0.000 description 1
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
-1 theophylline acetic acids Chemical class 0.000 description 1
238000001238 wet grinding Methods 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Neurology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

BG105378A 1998-09-15 2001-03-23 Лечение на депресия BG105378A (bg)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA199801163		1998-09-15
PCT/DK1999/000482 WO2000015225A1 (en)	1998-09-15	1999-09-14	Treatment of depression

Publications (1)

Publication Number	Publication Date
BG105378A true BG105378A (bg)	2001-12-29

Family

ID=8101704

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG105378A BG105378A (bg)	1998-09-15	2001-03-23	Лечение на депресия

Country Status (25)

Country	Link
US (1)	US6358966B2 (id)
EP (1)	EP1121122A1 (id)
JP (1)	JP2002524515A (id)
KR (1)	KR20010075120A (id)
CN (1)	CN1317969A (id)
AR (1)	AR021805A1 (id)
AU (1)	AU5617499A (id)
BG (1)	BG105378A (id)
BR (1)	BR9913964A (id)
CA (1)	CA2343761A1 (id)
CZ (1)	CZ2001946A3 (id)
EA (1)	EA200100355A1 (id)
HK (1)	HK1040922A1 (id)
HR (1)	HRP20010191A2 (id)
HU (1)	HUP0103568A3 (id)
ID (1)	ID29414A (id)
IL (1)	IL141880A0 (id)
IS (1)	IS5873A (id)
NO (1)	NO20011268L (id)
PL (1)	PL346528A1 (id)
SK (1)	SK3502001A3 (id)
TR (1)	TR200100767T2 (id)
WO (1)	WO2000015225A1 (id)
YU (1)	YU18701A (id)
ZA (1)	ZA200101910B (id)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR030453A1 (es) *	2000-08-15	2003-08-20	Lundbeck & Co As H	Composicion farmaceutica con contenido de 1' [4-[1-(4-fluorofenil)-1h-indol-3-il]-1-butil] espiro [isobenzofuran-1 (3h), 4'-piperidina]

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ243065A (en) *	1991-06-13	1995-07-26	Lundbeck & Co As H	Piperidine derivatives and pharmaceutical compositions
SK14842000A3 (sk) *	1998-04-07	2001-06-11	H. Lundbeck A/S	Použitie 1'-{4-[1-(4-fluórfenyl)-1h-indol-3-yl]-1-butyl}- -spiro[izobenzo-furán-1(3h),4'-piperidín]u na liečbu záchvatov paniky

1999
- 1999-09-14 ZA ZA200101910A patent/ZA200101910B/en unknown
- 1999-09-14 JP JP2000569809A patent/JP2002524515A/ja not_active Withdrawn
- 1999-09-14 ID IDW20010847A patent/ID29414A/id unknown
- 1999-09-14 YU YU18701A patent/YU18701A/sh unknown
- 1999-09-14 HK HK02102706.9A patent/HK1040922A1/zh unknown
- 1999-09-14 EA EA200100355A patent/EA200100355A1/ru unknown
- 1999-09-14 AR ARP990104606A patent/AR021805A1/es unknown
- 1999-09-14 KR KR1020017003328A patent/KR20010075120A/ko not_active Withdrawn
- 1999-09-14 TR TR2001/00767T patent/TR200100767T2/xx unknown
- 1999-09-14 CZ CZ2001946A patent/CZ2001946A3/cs unknown
- 1999-09-14 BR BR9913964-2A patent/BR9913964A/pt not_active Application Discontinuation
- 1999-09-14 HU HU0103568A patent/HUP0103568A3/hu unknown
- 1999-09-14 WO PCT/DK1999/000482 patent/WO2000015225A1/en not_active Ceased
- 1999-09-14 IL IL14188099A patent/IL141880A0/xx unknown
- 1999-09-14 CA CA002343761A patent/CA2343761A1/en not_active Abandoned
- 1999-09-14 CN CN99810945A patent/CN1317969A/zh active Pending
- 1999-09-14 SK SK350-2001A patent/SK3502001A3/sk unknown
- 1999-09-14 AU AU56174/99A patent/AU5617499A/en not_active Abandoned
- 1999-09-14 EP EP99942779A patent/EP1121122A1/en not_active Withdrawn
- 1999-09-14 PL PL99346528A patent/PL346528A1/xx unknown
- 1999-09-14 HR HR20010191A patent/HRP20010191A2/hr not_active Application Discontinuation
2001
- 2001-02-28 IS IS5873A patent/IS5873A/is unknown
- 2001-03-13 NO NO20011268A patent/NO20011268L/no not_active Application Discontinuation
- 2001-03-15 US US09/809,470 patent/US6358966B2/en not_active Expired - Fee Related
- 2001-03-23 BG BG105378A patent/BG105378A/bg unknown

Also Published As

Publication number	Publication date
PL346528A1 (en)	2002-02-11
IS5873A (is)	2001-02-28
CN1317969A (zh)	2001-10-17
ID29414A (id)	2001-08-30
HUP0103568A2 (hu)	2002-01-28
AR021805A1 (es)	2002-08-07
SK3502001A3 (en)	2001-12-03
CZ2001946A3 (cs)	2001-09-12
HUP0103568A3 (en)	2003-05-28
JP2002524515A (ja)	2002-08-06
BR9913964A (pt)	2001-07-03
YU18701A (sh)	2003-07-07
HK1040922A1 (zh)	2002-06-28
KR20010075120A (ko)	2001-08-09
EP1121122A1 (en)	2001-08-08
TR200100767T2 (tr)	2001-07-23
NO20011268L (no)	2001-05-15
US6358966B2 (en)	2002-03-19
IL141880A0 (en)	2002-03-10
WO2000015225A1 (en)	2000-03-23
NO20011268D0 (no)	2001-03-13
AU5617499A (en)	2000-04-03
ZA200101910B (en)	2001-09-11
US20010020027A1 (en)	2001-09-06
EA200100355A1 (ru)	2001-08-27
CA2343761A1 (en)	2000-03-23
HRP20010191A2 (en)	2002-04-30

Publication	Publication Date	Title
US7579370B2 (en)	2009-08-25	Fused heterocycles
DE60107435T2 (de)	2005-12-15	2-adamantylethylamine und deren verwendung bei der behandlung von abnormalitäten in der glutamat transmission
CN101754762A (zh)	2010-06-23	用于治疗神经炎症性疾病的包含哒嗪化合物的制剂
US20040024043A1 (en)	2004-02-05	Method for treating cognitive disorders
DE69933885T2 (de)	2007-05-24	Triphenylbutenderivate zur behandlung von neurologischen störungen
WO2024196799A2 (en)	2024-09-26	Isoindoline compositions and methods for treating neurodegenerative disease
WO2006004201A1 (ja)	2006-01-12	神経再生促進剤
US20100273769A1 (en)	2010-10-28	Composition and method for the treatment of parkinson's disease
BR112019016775A2 (pt)	2020-03-31	Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
KR102235994B1 (ko)	2021-04-05	환상 아민 유도체의 결정 및 그 의약 용도
CN1974545B (zh)	2010-05-26	长链脂肪酰胺类化合物及其应用
JP7295145B2 (ja)	2023-06-20	神経変性疾患を治療するための医薬及びその使用
KR102680403B1 (ko)	2024-07-04	피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물
JP2005508352A (ja)	2005-03-31	新規ベンゾチアジン誘導体、その製造方法及びその使用方法
JP2005538146A (ja)	2005-12-15	新規なピペリジン―２，６−ジオンパモエート塩類及びストレス関連情動性疾患を治療・処置するためにこれらを使用する方法
US6358966B2 (en)	2002-03-19	Treatment of depression
RU2799454C2 (ru)	2023-07-05	Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение
CN116554144B (zh)	2025-12-19	一种sj系列芳基苯胺类化合物及其制备方法与医药用途
MXPA01002661A (en)	2001-11-21	Treatment of depression
US20230064254A1 (en)	2023-03-02	Therapeutic agent containing fused pyrimidine compound as active ingredient
WO2015186144A2 (en)	2015-12-10	Method of inhibition of beta-secretase by using bis-o-demethylcurcumin for the prevention, management and treatment of neurodegenerative diseases
BR102020021141A2 (pt)	2022-04-26	Inibidores dos transportadores de prolina como fármacos para o tratamento de doenças psiquiátricas, neurológicas e neurodegenerativas
JP2011020957A (ja)	2011-02-03	アルツハイマー病治療薬